UP!
Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecular therapeutics for oncology and other unmet medical needs. The company was founded by Jim Wells.
Founded in 1998, Sunesis filed and completed an IPO in 2005. It is listed on NASDAQ as SNSS. [1]
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2020 | 2020-11-09 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-11 | -0.60 | -0.60 |
| Q1 2020 | 2020-05-07 | -0.50 | -0.50 |
| Q4 2019 | 2020-03-10 | -0.50 | -0.50 |
| Q3 2019 | 2019-11-12 | -0.60 | -0.60 |
| Q2 2019 | 2019-08-07 | -0.90 | -0.90 |
| Q1 2019 | 2019-05-08 | -1.00 | -1.00 |
| Q4 2018 | 2019-03-07 | -1.60 | -1.60 |
| Q3 2018 | 2018-11-05 | -1.80 | -1.80 |
| 2016-05-06 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-01-05 | Upgrade | Cantor Fitzgerald | Hold to Buy | |
| 2015-07-24 | Downgrade | Cantor Fitzgerald | Buy to Hold | $4.00 to $2.00 |
| 2015-07-24 | Downgrade | Cowen and Company | Outperform to Market Perform | |
| 2015-07-24 | Downgrade | Roth Capital | Buy to Sell | $5.50 to $1.00 |
| 2015-07-02 | Reiterated Rating | Wedbush | Hold | $2.00 |
| 2015-06-15 | Boost Price Target | Roth Capital | Buy | $4.00 to $5.50 |
| 2015-06-12 | Set Price Target | Wedbush | Hold | $2.00 |
| 2015-06-12 | Set Price Target | Cantor Fitzgerald | Buy | $4.00 |
| 2015-05-05 | Lower Price Target | Roth Capital | Buy | $4.30 to $4.00 |
| 2015-03-15 | Reiterated Rating | Cantor Fitzgerald | Buy | $4.00 |
| 2015-03-13 | Set Price Target | Roth Capital | Buy | $4.30 |
| 2015-01-06 | Initiated Coverage | BTIG Research | Buy | $5.50 |
| 2014-12-15 | Upgrade | Roth Capital | Neutral to Buy | $2.30 to $4.30 |
| 2014-12-10 | Upgrade | Cantor Fitzgerald | Hold to Buy | $2.00 to $4.00 |
| 2014-12-09 | Reiterated | ROTH Capital | Neutral | $1.30 to $2.30 |
| 2014-12-09 | Boost Price Target | Roth Capital | Neutral | $1.30 to $2.30 |
| 2014-10-07 | Downgrade | ROTH Capital | Buy to Neutral | $15 to $1.30 |
| 2014-10-07 | Downgrade | Cantor Fitzgerald | Buy to Hold | $2.00 |
| 2014-10-07 | Downgrade | Roth Capital | Buy to Neutral | $15.00 to $1.30 |
| 2014-10-06 | Downgrade | RBC Capital | Outperform to Sector Perform | $9.00 to $3.00 |
| 2014-10-06 | Reiterated Rating | Wedbush | Neutral | $10.00 to $2.00 |
| 2014-10-06 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | |
| 2014-10-06 | Downgrade | Wells Fargo | Outperform to Market Perform | |
| 2014-10-06 | Downgrade | Royal Bank Of Canada | Outperform to Sector Perform | $9.00 to $3.00 |
| 2014-08-29 | Downgrade | Wedbush | Outperform to Neutral | |
| 2014-03-10 | Boost Price Target | Cantor Fitzgerald | $8.00 to $14.00 | |
| 2014-03-05 | Boost Price Target | Leerink Swann | Outperform | $14.00 to $17.00 |
| 2014-02-25 | Boost Price Target | Leerink Swann | $10.00 to $14.00 | |
| 2012-09-11 | Reiterated | Cantor Fitzgerald | Buy | $6 to $8 |
| 2012-04-13 | Initiated | Cantor Fitzgerald | Buy | $6 |
| 2012-03-06 | Initiated | Canaccord Genuity | Buy | $4 |
| 2011-09-29 | Initiated | MLV Capital | Buy | $3.50 |
| 2016-05-06 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-01-05 | Upgrade | Cantor Fitzgerald | Hold to Buy | |
| 2015-07-24 | Downgrade | Cantor Fitzgerald | Buy to Hold | $4.00 to $2.00 |
| 2015-07-24 | Downgrade | Cowen and Company | Outperform to Market Perform | |
| 2015-07-24 | Downgrade | Roth Capital | Buy to Sell | $5.50 to $1.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SNSS 4 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| KCG Holdings, Inc. | 76910 |
| BlackRock Institutional Trust Company, N.A. | 76616 |
| BlackRock Fund Advisors | 3048 |
| BLACKROCK ADVISORS LLC | 2343 |
UM